Developer docs
API playgroundTry for free, no card

Search company profiles

Capricor Therapeutics, Inc.

Full company profile

uuid00yncft

Namestring
Capricor Therapeutics, Inc.
Legal namestring
Capricor Therapeutics, Inc.
Websiteurl
capricor.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapeutics for rare and serious diseases. The company's lead product candidate is Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell (CDC) therapy that targets Duchenne muscular dystrophy (DMD) and DMD-associated cardiomyopathy. Capricor's HOPE-2 and HOPE-3 trials have reported statistically significant preservation of cardiac function and met primary efficacy endpoints on upper limb performance, and the company has resubmitted a Biologics License Application with an FDA PDUFA target action date of August 22, 2026. Capricor has also developed the proprietary StealthX exosome platform, which enables adjuvant-free vaccine and therapeutic delivery of nucleic acids and proteins, with active programs in SARS-CoV-2 vaccination (under NIH Project NextGen) and preclinical rare-disease applications such as arginase-1 deficiency.

Short descriptiontext

Capricor Therapeutics is a clinical-stage biotechnology company developing allogeneic cardiosphere-derived cell therapies (Deramiocel) for Duchenne muscular dystrophy and a proprietary exosome platform (StealthX) for vaccines and therapeutic delivery.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy therapeutics, exosome-based therapeutics, duchenne muscular dystrophy treatment, biologic medicine development, regenerative medicine
Industry2 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Revenue (Future)
TypeOne Time License
Description

Capricor is pre-revenue with no commercialized products. The company anticipates potential revenue from Deramiocel (CAP-1002) sales pending FDA approval, with partnership arrangements with Nippon Shinyaku for US and Japan commercialization.

seekingalpha.com
2Partnership Milestone Payments
TypeLicensing Royalties
Description

The company receives or anticipates milestone payments from commercial partners including Nippon Shinyaku/NS Pharma contingent on regulatory and commercial milestones.

seekingalpha.com
3Government Grants
TypeProfessional Services
Description

Non-dilutive funding from NIH/Project NextGen supporting exosome vaccine development. The company has received grant funding for Phase 1 clinical studies with the StealthX vaccine.

capricor.com
4Public Offerings
TypeHardware Sales
Description

Capital raised through underwritten public offerings of common stock, including $150 million offering in December 2025 and $23 million offering in September 2023.

seekingalpha.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1StealthX™
Description

Proprietary exosome platform technology for vaccine and therapeutic development, including multivalent vaccine candidates for SARS-CoV-2 and exosome-based delivery of mRNA and other payloads.

capricor.com
+1 more record
Core offering1 text field

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy targeting Duchenne muscular dystrophy and associated cardiomyopathy. The company also operates the proprietary StealthX exosome platform for vaccine and therapeutic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 91% slowing of cardiac disease progression (preservation of left ventricular ejection fraction)
+1 more record
Product overview1 text field

Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics. The core product is Deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy currently under FDA review. Supporting this is the StealthX™ exosome platform technology, which enables delivery of nucleic acids and proteins for vaccine and therapeutic applications. The company operates with a multi-stage pipeline exploring allogeneic cardiosphere-derived cells and exosome science, with additional programs including a SARS-CoV-2 vaccine candidate under NIH Project NextGen collaboration and preclinical exosome programs for rare diseases.

Product and service4 records
1Deramiocel (CAP-1002)
Categorycell therapy
Description

An allogeneic cardiosphere-derived cell (CDC) therapy for treating Duchenne muscular dystrophy and associated cardiomyopathy. Currently in late-stage clinical development with Biologics License Application under FDA review (PDUFA target action date August 22, 2026).

2StealthX Exosome Platform
Categoryexosome technology platform
Description

Proprietary exosome-based technology platform for developing vaccines and therapeutics. Engineered exosomes capable of delivering nucleic acids, proteins, and other payloads to treat or prevent various diseases.

3StealthX SARS-CoV-2 Vaccine
Categoryvaccine candidate
Description

Multivalent exosome-based vaccine candidate targeting SARS-CoV-2, delivering both spike (S) and nucleocapsid (N) proteins. Part of NIH Project NextGen initiative with NIAID-conducted Phase 1 clinical study. The platform is free of adjuvant and lipid nanoparticles.

4StealthX ARG1-D Program
Categoryrare disease therapeutic
Description

Exosome-based therapeutic approach for arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease, utilizing engineered exosomes expressing human Arg1 enzyme.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-24
Description

Capricor's StealthX exosome-based multivalent vaccine for SARS-CoV-2 was selected for Project NextGen, an initiative by the U.S. Department of Health and Human Services. NIAID will conduct Phase 1 clinical study with Capricor's vaccine candidate. This collaboration provides non-dilutive funding for clinical advancement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-29
Description

Exclusive worldwide licensing agreement with Johns Hopkins University for engineered exosome technology for vaccines and therapeutics. The licensed technology is based on preclinical research conducted by Dr. Stephen Gould, who serves as Capricor's executive consultant. Capricor and JHU have collaborated over a decade on technologies in chronic heart failure, cardiovascular, genetic and muscular diseases.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-12
Description

Manufacturing collaboration with Lonza for the development of CAP-1002 for Duchenne muscular dystrophy and other indications. The partnership supports commercial-scale manufacturing capabilities.

4Cedars-Sinai Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-09-18
Description

Long-standing research collaboration with Cedars-Sinai Heart Institute. Clinical trials including ALLSTAR Phase I trial were conducted at Cedars-Sinai. Dr. Raj R. Makker presented Phase I results. Capricor was formed from merger with Nile Therapeutics in 2013, with roots in Cedars-Sinai research.

capricor.com
5Nippon Shinyaku Co., Ltd. / NS Pharma, Inc.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Capricor entered into a partnership with Nippon Shinyaku for exclusive commercialization and distribution of CAP-1002 for Duchenne muscular dystrophy in the United States and Japan. The partnership is subject to regulatory approval. Capricor has also filed a rescission action against Nippon Shinyaku and NS Pharma regarding the distribution agreement.

capricor.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mesoblast develops allogeneic cell therapies for inflammatory and cardiovascular diseases, including those derived from proprietary cell sources. Capricor's CAP-1002 (allogeneic cardiosphere-derived cells) shares allogeneic cell-therapy manufacturing, regulatory, and commercial dynamics with Mesoblast's portfolio.

TypeEmerging player
Description

CRISPR Therapeutics is a clinical-stage gene-editing biotech with overlapping modality (nucleic-acid delivery, ex vivo cell therapy). Capricor's exosome-mediated nucleic acid and protein delivery has conceptual overlap with CRISPR's therapeutic delivery challenges in monogenic disease.

TypeDirect peer
Description

PTC Therapeutics markets DMD therapies including Translarna (ataluren) and is developing additional DMD programs. Capricor and PTC both target the same neuromuscular specialists and DMD patient community with disease-modifying biologics.

TypeBroad incumbent
Description

BioMarin is an established rare-disease biotech with multiple approved biologics. Both companies operate in rare disease biologics with complex manufacturing and global distribution, providing a useful broader-incumbent benchmark for Capricor's commercialization path.

TypeBroad incumbent
Description

Vertex is a major biotech with established cell and gene therapy capabilities (notably in sickle cell disease and CASGEVY). Capricor's allogeneic CDC therapy and exosome-mediated nucleic acid delivery share cell-therapy manufacturing and regulatory dynamics with Vertex's modality.

TypeDirect peer
Description

Sarepta is the leading commercial-stage biotech focused exclusively on Duchenne muscular dystrophy. Both companies develop biologic therapies targeting DMD and compete for the same patient population and physician-prescriber base, making Sarepta Capricor's most direct competitive comparator.

TypeBroad incumbent
Description

Ultragenyx is a clinical and commercial rare-disease biotech advancing biologics and gene therapies. Capricor's StealthX enzyme-replacement programs (e.g., ARG1-D) and DMD cell therapy are directly comparable to Ultragenyx's rare-disease biologic pipeline.

TypeDirect peer
Description

Solid Biosciences develops gene and cell-based therapies for Duchenne muscular dystrophy. Both Capricor and Solid are clinical-stage DMD-focused biotechs developing next-generation biologics (cell therapy and gene therapy respectively) for the same monogenic disease.

9bluebird bio
TypeBroad incumbent
Description

bluebird bio develops gene and cell therapies for rare genetic diseases, requiring similar FDA regulatory pathways and complex biological manufacturing as Capricor's Deramiocel. Both companies target small rare-disease patient populations with high-cost biologic modalities.

TypeEmerging player
Description

Evox Therapeutics is a clinical-stage biotech focused on engineering extracellular vesicles/exosomes for nucleic acid and protein delivery to treat rare diseases. Evox is the closest direct peer to Capricor's StealthX exosome platform, sharing the engineered-exosome therapeutic modality.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Capricor Therapeutics, Inc.

Biopharmaceuticalscapricor.com

Capricor Therapeutics is a clinical-stage biotechnology company developing allogeneic cardiosphere-derived cell therapies (Deramiocel) for Duchenne muscular dystrophy and a proprietary exosome platform (StealthX) for vaccines and therapeutic delivery.

What Capricor Therapeutics, Inc. does

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapeutics for rare and serious diseases. The company's lead product candidate is Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell (CDC) therapy that targets Duchenne muscular dystrophy (DMD) and DMD-associated cardiomyopathy. Capricor's HOPE-2 and HOPE-3 trials have reported statistically significant preservation of cardiac function and met primary efficacy endpoints on upper limb performance, and the company has resubmitted a Biologics License Application with an FDA PDUFA target action date of August 22, 2026. Capricor has also developed the proprietary StealthX exosome platform, which enables adjuvant-free vaccine and therapeutic delivery of nucleic acids and proteins, with active programs in SARS-CoV-2 vaccination (under NIH Project NextGen) and preclinical rare-disease applications such as arginase-1 deficiency.

Capricor Therapeutics, Inc. firmographics

Firmographics
Name
Capricor Therapeutics, Inc.
Legal name
Capricor Therapeutics, Inc.
Website
https://capricor.com
Company type
Public
Founded year
2013
Operating status
Operating
Short description
Capricor Therapeutics is a clinical-stage biotechnology company developing allogeneic cardiosphere-derived cell therapies (Deramiocel) for Duchenne muscular dystrophy and a proprietary exosome platform (StealthX) for vaccines and therapeutic delivery.
Ownership category
akta.pro rank

Capricor Therapeutics, Inc. industry classification

Industry
Product category
Biopharmaceuticals
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cell therapy therapeutics
  • Exosome-based therapeutics
  • Duchenne muscular dystrophy treatment
  • Biologic medicine development
  • Regenerative medicine

Where Capricor Therapeutics, Inc. is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Capricor Therapeutics, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

  1. Product Revenue (Future): Capricor is pre-revenue with no commercialized products. The company anticipates potential revenue from Deramiocel (CAP-1002) sales pending FDA approval, with partnership arrangements with Nippon Shinyaku for US and Japan commercialization.
  2. Partnership Milestone Payments: The company receives or anticipates milestone payments from commercial partners including Nippon Shinyaku/NS Pharma contingent on regulatory and commercial milestones.
  3. Government Grants: Non-dilutive funding from NIH/Project NextGen supporting exosome vaccine development. The company has received grant funding for Phase 1 clinical studies with the StealthX vaccine.
  4. Public Offerings: Capital raised through underwritten public offerings of common stock, including $150 million offering in December 2025 and $23 million offering in September 2023.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Capricor Therapeutics, Inc. product offering

Product offering

Core offering

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy targeting Duchenne muscular dystrophy and associated cardiomyopathy. The company also operates the proprietary StealthX exosome platform for vaccine and therapeutic development.

Product overview

Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics. The core product is Deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy currently under FDA review. Supporting this is the StealthX™ exosome platform technology, which enables delivery of nucleic acids and proteins for vaccine and therapeutic applications. The company operates with a multi-stage pipeline exploring allogeneic cardiosphere-derived cells and exosome science, with additional programs including a SARS-CoV-2 vaccine candidate under NIH Project NextGen collaboration and preclinical exosome programs for rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • StealthX™: Proprietary exosome platform technology for vaccine and therapeutic development, including multivalent vaccine candidates for SARS-CoV-2 and exosome-based delivery of mRNA and other payloads.
  • Deramiocel

Products and services

  • Deramiocel (CAP-1002) An allogeneic cardiosphere-derived cell (CDC) therapy for treating Duchenne muscular dystrophy and associated cardiomyopathy. Currently in late-stage clinical development with Biologics License Application under FDA review (PDUFA target action date August 22, 2026).
  • StealthX Exosome Platform Proprietary exosome-based technology platform for developing vaccines and therapeutics. Engineered exosomes capable of delivering nucleic acids, proteins, and other payloads to treat or prevent various diseases.
  • StealthX SARS-CoV-2 Vaccine Multivalent exosome-based vaccine candidate targeting SARS-CoV-2, delivering both spike (S) and nucleocapsid (N) proteins. Part of NIH Project NextGen initiative with NIAID-conducted Phase 1 clinical study. The platform is free of adjuvant and lipid nanoparticles.
  • StealthX ARG1-D Program Exosome-based therapeutic approach for arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease, utilizing engineered exosomes expressing human Arg1 enzyme.

Quantifiable outcome

  • 91% slowing of cardiac disease progression (preservation of left ventricular ejection fraction)
  • +1 more outcomes

Companies that use Capricor Therapeutics, Inc.

Customer profile

Segments1 record

Ideal customer profiles2 records

Capricor Therapeutics, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Capricor Therapeutics, Inc. partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • National Institutes of Health (NIH) / Project NextGenflagshipStrategic or Co-development Partner · 24 January 2024Capricor's StealthX exosome-based multivalent vaccine for SARS-CoV-2 was selected for Project NextGen, an initiative by the U.S. Department of Health and Human Services. NIAID will conduct Phase 1 clinical study with Capricor's vaccine candidate. This collaboration provides non-dilutive funding for clinical advancement.
  • Johns Hopkins UniversitycoreStrategic or Co-development Partner · 29 April 2021Exclusive worldwide licensing agreement with Johns Hopkins University for engineered exosome technology for vaccines and therapeutics. The licensed technology is based on preclinical research conducted by Dr. Stephen Gould, who serves as Capricor's executive consultant. Capricor and JHU have collaborated over a decade on technologies in chronic heart failure, cardiovascular, genetic and muscular diseases.
  • LonzacoreTechnology or Integration · 12 January 2021Manufacturing collaboration with Lonza for the development of CAP-1002 for Duchenne muscular dystrophy and other indications. The partnership supports commercial-scale manufacturing capabilities.
  • Cedars-Sinai Medical CentercoreStrategic or Co-development Partner · 18 September 2014Long-standing research collaboration with Cedars-Sinai Heart Institute. Clinical trials including ALLSTAR Phase I trial were conducted at Cedars-Sinai. Dr. Raj R. Makker presented Phase I results. Capricor was formed from merger with Nile Therapeutics in 2013, with roots in Cedars-Sinai research.
  • Nippon Shinyaku Co., Ltd. / NS Pharma, Inc.coreChannel Partner/ Reseller/ DistributorCapricor entered into a partnership with Nippon Shinyaku for exclusive commercialization and distribution of CAP-1002 for Duchenne muscular dystrophy in the United States and Japan. The partnership is subject to regulatory approval. Capricor has also filed a rescission action against Nippon Shinyaku and NS Pharma regarding the distribution agreement.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Capricor Therapeutics, Inc. competitors and assessment

Company assessment

Direct peers

  • Mesoblast: Mesoblast develops allogeneic cell therapies for inflammatory and cardiovascular diseases, including those derived from proprietary cell sources. Capricor's CAP-1002 (allogeneic cardiosphere-derived cells) shares allogeneic cell-therapy manufacturing, regulatory, and commercial dynamics with Mesoblast's portfolio.
  • PTC Therapeutics: PTC Therapeutics markets DMD therapies including Translarna (ataluren) and is developing additional DMD programs. Capricor and PTC both target the same neuromuscular specialists and DMD patient community with disease-modifying biologics.
  • Sarepta Therapeutics: Sarepta is the leading commercial-stage biotech focused exclusively on Duchenne muscular dystrophy. Both companies develop biologic therapies targeting DMD and compete for the same patient population and physician-prescriber base, making Sarepta Capricor's most direct competitive comparator.
  • Solid Biosciences: Solid Biosciences develops gene and cell-based therapies for Duchenne muscular dystrophy. Both Capricor and Solid are clinical-stage DMD-focused biotechs developing next-generation biologics (cell therapy and gene therapy respectively) for the same monogenic disease.

Emerging players

  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene-editing biotech with overlapping modality (nucleic-acid delivery, ex vivo cell therapy). Capricor's exosome-mediated nucleic acid and protein delivery has conceptual overlap with CRISPR's therapeutic delivery challenges in monogenic disease.
  • Evox Therapeutics: Evox Therapeutics is a clinical-stage biotech focused on engineering extracellular vesicles/exosomes for nucleic acid and protein delivery to treat rare diseases. Evox is the closest direct peer to Capricor's StealthX exosome platform, sharing the engineered-exosome therapeutic modality.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is an established rare-disease biotech with multiple approved biologics. Both companies operate in rare disease biologics with complex manufacturing and global distribution, providing a useful broader-incumbent benchmark for Capricor's commercialization path.
  • Vertex Pharmaceuticals: Vertex is a major biotech with established cell and gene therapy capabilities (notably in sickle cell disease and CASGEVY). Capricor's allogeneic CDC therapy and exosome-mediated nucleic acid delivery share cell-therapy manufacturing and regulatory dynamics with Vertex's modality.
  • Ultragenyx Pharmaceutical: Ultragenyx is a clinical and commercial rare-disease biotech advancing biologics and gene therapies. Capricor's StealthX enzyme-replacement programs (e.g., ARG1-D) and DMD cell therapy are directly comparable to Ultragenyx's rare-disease biologic pipeline.
  • bluebird bio: bluebird bio develops gene and cell therapies for rare genetic diseases, requiring similar FDA regulatory pathways and complex biological manufacturing as Capricor's Deramiocel. Both companies target small rare-disease patient populations with high-cost biologic modalities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Capricor Therapeutics, Inc. social profiles

Digital presence

Capricor Therapeutics, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Capricor Therapeutics, Inc. leadership team

Management profile

Number of profiles

Profiles9 records

Capricor Therapeutics, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Capricor Therapeutics, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capricor Therapeutics, Inc.

What does Capricor Therapeutics, Inc. do?

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy targeting Duchenne muscular dystrophy and associated cardiomyopathy. The company also operates the proprietary StealthX exosome platform for vaccine and therapeutic development.

Is Capricor Therapeutics, Inc. a public or private company?

Capricor Therapeutics, Inc. is a public company. It is classified as public and is currently operating.

When was Capricor Therapeutics, Inc. founded?

Capricor Therapeutics, Inc. was founded in 2013.

Where is Capricor Therapeutics, Inc. based?

Capricor Therapeutics, Inc. is headquartered in San Diego, United States, in the North America region.

How does Capricor Therapeutics, Inc. make money?

Four revenue lines are on record. Product Revenue (Future) is the primary driver. The others are partnership Milestone Payments, government Grants and public Offerings.

Who are Capricor Therapeutics, Inc.'s main competitors?

Direct peers on record are Mesoblast, PTC Therapeutics, Sarepta Therapeutics and Solid Biosciences. Emerging players are CRISPR Therapeutics and Evox Therapeutics. Broad incumbents are BioMarin Pharmaceutical, Vertex Pharmaceuticals, Ultragenyx Pharmaceutical and bluebird bio.

Does Capricor Therapeutics, Inc. have an API?

No public API is recorded for Capricor Therapeutics, Inc..

What industry is Capricor Therapeutics, Inc. in?

Capricor Therapeutics, Inc.'s product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRRosen Law Firm issued a press release on August 25, 2026 urging purchasers of Capricor Therapeutics securities between December 17, 2025 and July 26, 2026 to act as lead plaintiff in a filed securities class action. Investors must move to serve as lead plaintiff by September 28, 2026, with no class certified. The suit alleges false statements about changes to the statistical analysis plan for Deramiocel and FDA approval risks.FinancialContent Business PageINVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action LawsuitA securities fraud class action against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleges material misstatements and omissions about its lead product Deramiocel's statistical analysis plan and FDA compliance. The complaint cites FDA briefing documents released July 27, 2026, which said Capricor changed the pre-specified plan after submission and the FDA disagreed with the conversion method. Capricor stock fell 64% on July 27. Investors may seek lead plaintiff status by September 28, 2026.PR NewswireCAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for InvestorsBleichmar Fonti & Auld LLP announced on August 25, 2026 that a securities fraud class action, Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385, was filed in the U.S. District Court for the Southern District of California against Capricor and certain executives. The complaint alleges false statements about Deramiocel and the integrity of clinical data supporting its Biologics License Application, citing a 64.5% drop to $7.00 on July 27, 2026. Investors have until September 28, 2026 to seek lead plaintiff status.GurufocusCapricor Therapeutics, Inc. Sued for Securities Law Violations -The DJS Law Group has announced a class action lawsuit against Capricor Therapeutics, Inc. alleging violations of securities laws due to false and misleading statements regarding its drug Deramiocel. The complaint alleges that Capricor modified the statistical analysis plan for clinical data without securing prior agreement from the FDA before resubmitting its Biologics License Application. Shareholders who purchased shares between December 17, 2025, and July 26, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointments.GurufocusCAPR Investors Have Opportunity to Lead Capricor Therapeutics, ISchall, Brown & Schwartz LLP is soliciting lead plaintiffs for a securities class action lawsuit against Capricor Therapeutics, Inc. The suit alleges that the company made false and misleading statements regarding its clinical data analysis and FDA approval process for Deramiocel during the period from December 17, 2025, to July 26, 2026. Investors who suffered losses are encouraged to contact the firm by September 28, 2026, to potentially join the litigation.PR NewswireCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRThe DJS Law Group has filed a class action lawsuit against Capricor Therapeutics, Inc., alleging violations of federal securities laws regarding the company's public statements. The complaint claims Capricor materially misled investors by modifying statistical analysis for its drug Deramiocel and failing to secure FDA agreement before resubmitting its Biologics License Application. Investors who purchased shares between December 17, 2025, and July 26, 2026, are encouraged to seek lead plaintiff status.PR NewswireCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP has filed a securities fraud class action lawsuit against Capricor Therapeutics regarding alleged false statements about its Deramiocel clinical data and FDA approval process. The complaint alleges the company changed statistical analysis plans without FDA agreement, leading to investor losses during the class period from December 2025 to July 2026. The lawsuit seeks to recover damages for shareholders who purchased stock within this timeframe.NewsfileROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRRosen Law Firm is reminding investors of Capricor Therapeutics, Inc. of the September 28, 2026 deadline to apply for lead plaintiff status in a pending securities class action. The lawsuit alleges that Capricor made misleading statements regarding its Deramiocel clinical data analysis and FDA regulatory interactions, causing investor damages. Investors purchased shares between December 17, 2025, and July 26, 2026, may be entitled to compensation through a contingency fee arrangement.NewsfileROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRThe Rosen Law Firm is encouraging investors to secure legal counsel before the September 28, 2026 deadline to serve as lead plaintiff in a securities class action against Capricor Therapeutics. The lawsuit alleges that Capricor made misleading statements regarding changes to its statistical analysis plan for Deramiocel and the lack of FDA agreement on those changes prior to resubmitting its Biologics License Application. Investors who purchased securities between December 17, 2025, and July 26, 2026, may be entitled to compensation if they can prove these disclosures caused damages.FinancialContent Business PageROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRRosen Law Firm is soliciting lead plaintiffs for a securities class action against Capricor Therapeutics, Inc., setting a deadline of September 28, 2026. The lawsuit alleges that the company made misleading statements regarding changes to its statistical analysis plan for Deramiocel and the FDA's agreement to those changes prior to resubmitting its Biologics License Application. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are being encouraged to join the litigation.